Incidence, prevalence, and antithrombotic management of atrial fibrillation in elderly Germans

Europace

Volumn 15, Issue 10, 2013, Pages 1437-1444

  Ohlmeier, Christoph ^a   Mikolajczyk, Rafael ^a,b,c   Haverkamp, Wilhelm ^d   Garbe, Edeltraut ^a,e  

^a LEIBNIZ INSTITUTE FOR PREVENTION RESEARCH AND EPIDEMIOLOGY BIPS   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e UNIVERSITY OF BREMEN   (Germany)

Author keywords

Antithrombotic medication; Atrial fibrillation; Epidemiology; Germany; Health insurance data

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; HEPARIN; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR; FIBRINOLYTIC AGENT;

AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; FEMALE; GERIATRIC PATIENT; GERMANY; HEALTH INSURANCE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; AGE; ATRIAL FIBRILLATION; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; FEMALE; FIBRINOLYTIC AGENTS; GERMANY; GUIDELINE ADHERENCE; HUMANS; INCIDENCE; MALE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885003576     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut048     Document Type: Article

References (29)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
3. Kimura K, Minematsu K, Yamaguchi T. Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2005;76:679-83.
4. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-4.
5. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25.
6. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9.
7. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on atrial fibrillation. Eur Heart J 2005;26:2422-34.
8. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009;11:423-34.
9. Schnabel RB, Wilde S, Wild PS, Munzel T, Blankenberg S. Atrial fibrillation: its prevalence and risk factor profile in the German general population. Dtsch Arztebl Int 2012;109:293-9.
10. McBride D, Bruggenjurgen B, Roll S, Willich SN. Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. J Thromb Thrombolysis 2007;24:65-72.
11. Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P. Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol 2011;100:897-905.
12. Pigeot I, Ahrens W. Establishment of a pharmacoepidemiological database in Germany: methodological potential, scientific value and practical limitations. Pharmacoepidemiol Drug Saf 2008;17:215-23.
13. Garbe E, Suling M, Kloss S, Lindemann C, Schmid U. Linkage of mother-baby pairs in the German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf 2011;20:258-64.
14. DIMDI German Institute of Medical Documentation and Information. International Statistical Classification of Diseases and Related Health Problems, 10th Revision: Version 2008. http://www.dimdi.de/static/de/klassi/icd- 10-gm/index.htm
15. Vaughan Williams EM. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129-47.
16. Newcombe RG, Altman DG. Proportions and their differences. In Altman DG, Machin D, Bryant TN, Gardner MJ (eds). Statistics with Confidence. 2nd ed. Bristol: BMJ Books; 2010.
17. Fay MP, Feuer EJ. Confidence intervals for directly standardized rates: a method based on the gamma distribution. Stat Med 1997;16:791-801.
18. Daly LE. Confidence limits made easy: interval estimation using a substitution method. Am J Epidemiol 1998;147:783-90.
19. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
20. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 2012, (EPUB ahead of print: [6 December 2012]).
21. Göpffarth D, Gress S, Jacobs K, Wasem J. Jahrbuch Risikostrukturausgleich 2009/2010: Von der Selektion zur Manipulation? Heidelberg: Medhochzwei; 2010.
22. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31: 2369-429.
23. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. J Interv Card Electrophysiol 2000;4: 369-82.
24. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96: 2455-61.
25. Alonso A, Agarwal SK, Soliman EZ, Ambrose M, Chamberlain AM, Prineas RJ et al. Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2009;158:111-7.
26. Dewilde S, Carey IM, Emmas C, Richards N, Cook DG. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart 2006;92:1064-70.
27. Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A et al. Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011;105: 1010-23.
28. Wilke T, Groth A, Mueller S, Pfannkuche M, Verheyen F, Linder R et al. Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Thromb Haemost 2012;107:1053-65.
29. Schink T, Garbe E. Representativity of dispensations of non-steroidal antiinflammatory drugs (NSAIDs) in the German Pharmacoepidemiological Research Database. Pharmacoepidemiol Drug Saf 2010;19(S1):S294.